CareLit · DOI-Nachweis · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 In…
DOI 10.1055/s-0046-1819806
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Reinisch, J Cortes, A Bardia, K Punie, C Barrios, S Hurvitz, A Schneeweiss, J Sohn, E Tokunaga, A Brufsky, Y H Park, B Xu, R Hegg, M Oliveira, A Fabi, N Vaksman, T Valdez, X Zhang, C Lai, S Tolaney
ZeitschriftSenologie - Zeitschrift für Mammadiagnostik und -therapie
Ausgabe02/2026
Jahrgang / SeitenJg. 23 · S. e32-e34
Kernaussage aus der Literatur
Abstract-Vorschau
Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-(L)1)
Zitieren
Zitierempfehlung
M Reinisch, J Cortes, A Bardia, K Punie, C Barrios, S Hurvitz, A Schneeweiss, J Sohn, E Tokunaga, A Brufsky, Y H Park, B Xu, R Hegg, M Oliveira, A Fabi, N Vaksman, T Valdez, X Zhang, C Lai, S Tolaney (2026) Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-(L)1). Senologie - Zeitschrift für Mammadiagnostik und -therapie, 23 (02), e32-e34. https://doi.org/10.1055/s-0046-1819806
Mit CareLit weiterarbeiten